Merck & Co., Inc. (NYSE:MRK) Sets New 1-Year High at $87.99

Share on StockTwits

Merck & Co., Inc. (NYSE:MRK) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $87.99 and last traded at $86.85, with a volume of 548034 shares trading hands. The stock had previously closed at $87.18.

MRK has been the topic of a number of recent research reports. Mizuho boosted their target price on Merck & Co., Inc. from $97.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Leerink Swann assumed coverage on Merck & Co., Inc. in a research note on Thursday, August 15th. They set an “outperform” rating and a $103.00 price target for the company. Svb Leerink initiated coverage on Merck & Co., Inc. in a report on Friday, August 16th. They set an “outperform” rating and a $103.00 price target for the company. JPMorgan Chase & Co. set a $96.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, Credit Suisse Group restated a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $95.47.

The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84. The business has a 50-day simple moving average of $84.54 and a 200-day simple moving average of $83.57. The stock has a market cap of $221.96 billion, a P/E ratio of 20.01, a PEG ratio of 1.89 and a beta of 0.52.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 48.16%. The company had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The company’s quarterly revenue was up 14.9% compared to the same quarter last year. On average, analysts predict that Merck & Co., Inc. will post 5.15 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 8th. Investors of record on Monday, December 16th will be paid a $0.61 dividend. The ex-dividend date is Friday, December 13th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.55. This represents a $2.44 dividend on an annualized basis and a yield of 2.81%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Titan Capital Management LLC CA acquired a new position in shares of Merck & Co., Inc. during the second quarter worth approximately $25,000. LFA Lugano Financial Advisors SA grew its stake in shares of Merck & Co., Inc. by 250.0% in the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares during the last quarter. JJJ Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. in the second quarter worth $27,000. Cumberland Partners Ltd bought a new position in Merck & Co., Inc. during the second quarter worth $40,000. Finally, Fusion Family Wealth LLC increased its position in Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares during the period. Hedge funds and other institutional investors own 74.53% of the company’s stock.

Merck & Co., Inc. Company Profile (NYSE:MRK)

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: How prevalent are 12b-1 fees?

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.